Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy

Prostate

Volumn 69, Issue 12, 2009, Pages 1325-1333

  You, Benoit ^a,b,c   Girard, Pascal ^a,b   Paparel, Philippe ^c   Freyer, Gilles ^a,b,c   Ruffion, Alain ^c   Charrié, Anne ^c   Hénin, Emilie ^a,b   Tod, Michel ^a,b,d   Perrin, Paul ^c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d Institut Cochin   (France)

Author keywords

Biomarker; Metabolite clearance rate; Prognosis; Prostate cancer; Prostate specific antigen; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 67650917743     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20978     Document Type: Article

References (28)

1. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy treated patients. J Urol 1989;141:1076-1083.
2. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-369.
3. Stephenson AJ, Kattan MW,Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT.Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-3978.
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical, (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-523.
5. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23:6992-6998.
6. Bolla M, van PH, Collette L, van CP, Vekemans K, Da PL, de Reijke TM, Verbaeys A, Bosset JF, van VR, Marechal JM, Scalliet P, Haustermans K, Pierart M. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-578.
7. You B, Perrin P, Freyer G, Ruffion A, Tranchand B, Henin E, Paparel P, Ribba B, Devonec M, Falandry C, Fournel C, Tod M, Girard P. Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clin Biochem 2008; 41:785-795.
8. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15:153-171.
9. Beal SL, Sheiner LB, Boeckmann A. NONMEM users guides. Ellicott City, Maryland, USA: Icon Development Solutions, 2006.
10. Brandle E, Hautmann O, Bachem M, Kleinschmidt K, Gottfried HW, Grunert A, Hautmann RE. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy-a critical assessment. Urology 1999;53: 722-730.
11. Gregorakis AK, Malovrouvas D, Stefanakis S, Petraki K, Scorilas A. Free/total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Clin Chim Acta 2005;357:196-201.
12. Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, Schnorr D, Loening SA. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 1997;35:591-595.
13. May M, Gunia S, Helke C, Braun KP, Pickenhain S, Hoschke B. Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model? Int J Biol Markers 2005;20:112-118.
14. Iwanicki-Caron I, Di Fiore F, Stetiu M, Tougeron D, Tougeron S, Benichou J, Basuyau J, Michel P. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008;26:3681-3686.
15. Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol 2008;109:194-198.
16. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007;46:221-234.
17. Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. J Clin Pharmacol 2007;64:603-612.
18. Retout S, Duffull S, Mentre F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001;65:141-151.
19. Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V, Boccon-Gibod L. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate 1995;26:334-338.
20. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-772.
21. Ravery V, Meulemans A, Boccon-Gibod L. Clearance of free and total serum PSA after prostatic surgery. Eur Urol 1998;33:251-254.
22. van Straalen JP, Bossens MM, de Reijke TM, Sanders GT. Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 1994;32:53-55.
23. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003;119:80-89.
24. Di FG, Zezza A, Nicolai M, Lombardi G, Cipollone G, Iantorno R, Boni R, Tenaglia R. Half-life of blood PSA after radical prostatectomy. Correlations with pathological stage and clinical course of the disease. Arch Ital Urol Androl 1997;69 (Suppl 1) 97-100.
25. Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD, Boyett J. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. Urology 1990;36:415-419.
26. Schaefer U, Witt F, Schueller P, Micke O, Willich N. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation. Anticancer Res 2000;20:4989-4992.
27. Semjonow A, Hamm M, Rathert P. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 1993;11:218-220.
28. Brandle E, Gottfried HW, Maier S, Flohr P, Steinbach G, Hautmann RE. Is radical prostatectomy a suitable model for determination of PSA half-life?. Urologe A 1995;34:419-423.